

Ian Dick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8092247/publications.pdf>

Version: 2024-02-01

33
papers

1,838
citations

331670

21
h-index

395702

33
g-index

33
all docs

33
docs citations

33
times ranked

2294
citing authors

#	ARTICLE	IF	CITATIONS
1	What's next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination. <i>OncImmunology</i> , 2022, 11, 2038403.	4.6	7
2	Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	3
3	Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma. <i>Genome Medicine</i> , 2022, 14, .	8.2	24
4	Neutrophil-to-lymphocyte ratio in malignant pleural fluid: Prognostic significance. <i>PLoS ONE</i> , 2021, 16, e0250628.	2.5	4
5	Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma. <i>OncImmunology</i> , 2020, 9, 1684713.	4.6	12
6	Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 584423.	4.8	39
7	Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome. <i>OncImmunology</i> , 2020, 9, 1684714.	4.6	12
8	Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment. <i>OncImmunology</i> , 2019, 8, e1641390.	4.6	22
9	Neo-antigen specific T cell responses indicate the presence of metastases before imaging. <i>Scientific Reports</i> , 2019, 9, 14640.	3.3	3
10	Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations. <i>Lung Cancer</i> , 2018, 119, 64-70.	2.0	23
11	Combination immune checkpoint blockade as an effective therapy for mesothelioma. <i>OncImmunology</i> , 2018, 7, e1494111.	4.6	37
12	Transient Treg depletion enhances therapeutic anti-cancer vaccination. <i>Immunity, Inflammation and Disease</i> , 2017, 5, 16-28.	2.7	33
13	Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma. <i>BMC Cancer</i> , 2017, 17, 396.	2.6	30
14	A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ. <i>Cancer Genomics and Proteomics</i> , 2017, 14, 103-118.	2.0	34
15	Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo. <i>Scientific Reports</i> , 2016, 6, 32643.	3.3	85
16	Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers. <i>Biomarkers</i> , 2016, 21, 551-561.	1.9	5
17	Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations. <i>Scientific Reports</i> , 2015, 5, 12298.	3.3	63
18	Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma. <i>BMC Cancer</i> , 2015, 15, 983.	2.6	13

#	ARTICLE	IF	CITATIONS
19	Discovery of new biomarkers for malignant mesothelioma. <i>Current Pulmonology Reports</i> , 2015, 4, 15-21.	1.3	27
20	Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma. <i>Gene</i> , 2015, 563, 103-105.	2.2	27
21	Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen. <i>Oncoimmunology</i> , 2015, 4, e1011492.	4.6	26
22	Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma. <i>Disease Markers</i> , 2014, 2014, 1-10.	1.3	24
23	Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. <i>Thorax</i> , 2014, 69, 895-902.	5.6	128
24	Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity. <i>PLoS ONE</i> , 2013, 8, e61895.	2.5	129
25	Estrogen and androgen regulation of plasma membrane calcium pump activity in immortalized distal tubule kidney cells. <i>Molecular and Cellular Endocrinology</i> , 2003, 212, 11-18.	3.2	42
26	Regulation of the 1b Isoform of the Plasma Membrane Calcium Pump by 1,25-Dihydroxyvitamin D3 in Rat Osteoblast-Like Cells. <i>Journal of Bone and Mineral Research</i> , 2001, 16, 525-534.	2.8	11
27	Phytoestrogens Reduce Bone Loss and Bone Resorption in Oophorectomized Rats. <i>Journal of Nutrition</i> , 1997, 127, 1795-1799.	2.9	127
28	Exercise effects on bone mass in postmenopausal women are site-specific and load-dependent. <i>Journal of Bone and Mineral Research</i> , 1996, 11, 218-225.	2.8	382
29	Oestrogen effects on calcitriol levels in postmenopausal women: a comparison of oral versus transdermal administration. <i>Clinical Endocrinology</i> , 1995, 43, 219-224.	2.4	37
30	The effects of menopause and age on calcitropic hormones: A cross-sectional study of 655 healthy women aged 35 to 90. <i>Journal of Bone and Mineral Research</i> , 1995, 10, 835-842.	2.8	99
31	The effects of calcium supplementation (milk powder or tablets) and exercise on bone density in postmenopausal women. <i>Journal of Bone and Mineral Research</i> , 1995, 10, 1068-1075.	2.8	283
32	Correlates of intestinal calcium absorption in women 10 years past the menopause. <i>Calcified Tissue International</i> , 1993, 52, 358-360.	3.1	37
33	Importance of bone resorption in the determination of bone density in women more than 10 years past the menopause. <i>Journal of Bone and Mineral Research</i> , 1993, 8, 1273-1279.	2.8	10